Table 2.

Treatment-emergent adverse events

Patients (N=20)	Grade 1–2	Grade 3–4
Neutropenia	6 (30)	11 (55)
Other infections	5 (23)	6 (30)
ALT increased	12 (60)	3 (15)
Skin rash	8 (40)	2 (10)
Anemia	12 (60)	2 (10)
AST increase	12 (60)	2 (10)
ALP increased	4 (20)	1 (5)
Infusion-related reaction	6 (30)	1 (5)
Myocarditis	0 (0)	1 (5)
Fatigue	13 (65)	0 (0)
Thrombocytopenia	10 (50)	0 (0)
Creatinine increase	10 (50)	0 (0)
Musculo-skeletal pain	9 (45)	0 (0)
Constipation	7 (35)	0 (0)
Nausea	5 (25)	0 (0)
COVID infection	5 (25)	0 (0)
Hyponatremia	4 (20)	0 (0)
Diarrhea	4 (20)	0 (0)
Dizziness	4 (20)	0 (0)
Bilirubin increase	4 (20)	0 (0)
Peripheral neuropathy	3 (15)	0 (0)
Headache	3 (15)	0 (0)
Hypercalcemia	3 (15)	0 (0)
Xerostomia	2 (10)	0 (0)
Mucositis	2 (10)	0 (0)

ALT, alanine transferase; AST, aspartate transferase; ALP, alkaline phosphatase